Berberine inhibits inflammatory activation of rat brain microglia

Neural Regeneration Research

Volumn 5, Issue 18, 2010, Pages 1384-1390

  Nam, Kyong Nyon ^a   Kim, Jae Hong ^b   Jung, Hoon Ji ^a   Park, Jung Mi ^b   Moon, Sang Kwan ^b   Kim, Young Suk ^b   Kim, Sun Yeou ^a   Lee, Eunjoo H ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Berberine; Brain inflammation; Interleukin 1 ; Microglia; Nitric oxide; Nuclear factor kappa; Prostaglandin; Tumor necrosis factor

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BERBERINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; NITRIC OXIDE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME RELEASE; IMMUNE RESPONSE; INTRACELLULAR MEMBRANE; MICROGLIA; MOUSE; NERVE STIMULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT;

EID: 79960411666     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2010.18.004     Document Type: Article

References (47)

1. Kaur G, Han SJ, Yang I, et al. Microglia and central nervous system immunity. Neurosurg Clin N Am. 2010;21(1):43-51.
2. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol. 2010;119(1):89-105.
3. Frank-Cannon TC, Alto LT, McAlpine FE, et al. Does neuroinflammation fan the flame in neurodegenerative disease? Mol Neurodegener. 2009;16:4-47.
4. Sugama S, Takenouchi T, Cho BP, et al. Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm Allergy Drug Targets. 2009;8(4):277-284.
5. McCarty MF. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses. 2006;67:251-269.
6. Ye M, Fu S, Pi R, et al. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol. 2009;61(7):831-837.
7. Cho KH, Kang HS, Jung WS, et al. Efficacy and safety of chunghyul-dan (qingwie-dan) in patients with hypercholesterolemia. Am J Chin Med. 2005;33(2):241-248.
8. Issat T, Jakobisiak M, Golab J. Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway. Oncol Rep. 2006; 16(6):1273-1276.
9. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351.
10. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004;203(2):127-137.
11. Lee CH, Chen JC, Hsiang CY, et al. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res. 2007;56(3): 193-201.
12. Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin. 2004;25(4):496-502.
13. Liu W, Tang F, Deng Y, et al. Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition. Mol Cell Biochem. 2009;325(1-2): 99-105.
14. Yin J, Gao Z, Liu D, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2007;294(1):E148-E156.
15. Cui HS, Matsumoto K, Murakami Y, et al. Berberine exerts neuroprotective actions against in vitro ischemia-induced neuronal cell damage in organotypic hippocampal slice cultures: involvement of B-cell lymphoma 2 phosphorylation suppression. Biol Pharm Bull. 2009;32(1):79-85.
16. Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neuroscience. 2006;7:78.
17. Huang L, Shi A, He F, et al. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010;18(3): 1244-1251.
18. Tao J, Zhang X, Ye W, et al. Chemical constituents from Corydalis humosa. Zhong Yao Cai. 2005;28(7):556-557.
19. Xiao HT, Peng J, Liang Y, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2010;16:1-5.
20. Qin L, Liu Y, Wang T, et al. NADPH oxidase mediates lipopolysaccharide-induced neurotixicity and proinflammatory gene expression in activated microglia. J Biol Chem. 2004;279(2): 1415-1421.
21. Bonaiuto C, McDonald PP, Rossi F, et al. Activation of nuclear factor-kappaB by beta-amyloid peptides and interferon-gamma in murine microglia. J Neuroimmunol. 1997;77(1):51-56.
22. Koudinov A, Kezlya E, Koudinova N, et al. Amyloid-beta, tau protein, and oxidative changes as a physiological compensatory mechanism to maintain CNS plasticity under Alzheimer's disease and other neurodegenerative conditions. J Alzheimers Dis. 2009; 18(2):381-400.
23. Hashioka S, Han YH, Fuji S, et al. Phosphatidylserine and phosphatidylcholine-containing liposomes inhibit amyloid and interferon- gamma-induced microglial activation. Free Radic Biol Med. 2007;42(7):945-954.
24. Li M, Pisalyaput K, Galvan M, et al. Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity. J Neurochem. 2004;91(3): 623-633.
25. Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995; 374(6523):647-650.
26. Kubo T, Nishimura S, Kumagae Y, et al. In vivo conversion of racemized beta-amyloid ([D-Ser26]beta-40) to truncated and toxic fragments ([D-Ser26] beta -35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res. 2002;70(3): 474-483.
27. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, et al. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem. 1995;64(1):253-265.
28. Frozza RL, Horn AP, Hoppe JB, et al. A comparative study of beta-amyloid peptides Abeta1-42 and Abeta25-35 toxicity in organotypic hippocampal slice cultures. Neurochem Res. 2009; 34(2):295-303.
29. Lu P, Mamiya T, Lu LL, et al. Silibinin attenuates amyloid beta25-35 peptide-induced memory impairments: implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice. J Pharmacol Exp Ther. 2009;331(1):319-326.
30. Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol. 1999;58(3): 233-247.
31. Jeong HW, Hsu KC, Lee JW, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009;296(4): E955-E964.
32. Kim S, Kim Y, Kim JE, et al. Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes. Phytomedicine. 2008;15(5):340-347.
33. Yoo KY, Hwang IK, Kim JD, et al. Antiinflammatory effect of the ethanol extract of Berberis koreana in a gerbil model ofcerebral ischemia/reperfusion. Phytother Res. 2008;22(11):1527-1532.
34. Zhou XQ, Zeng XN, Kong H, et al. Neuroprotective effects of berberine on stroke models in vitro and in vivo. Neurosci Lett. 2008;447(1):31-36.
35. Kheir MM, Wang Y, Hua L, et al. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol. 2010;48(4):1105-1110.
36. Chen FL, Yang ZH, Liu Y, et al. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine. 2008;33(3):331-337.
37. Calzado MA, Bacher S, Schmitz ML. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem. 2007;14(3):367-376.
38. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-kappaB): an emerging theme in anti-nflammatorytherapies. Mol Interv. 2002;2(1):22-35.
39. Li R, Huang YG, Fang D, et al. Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J Neurosci Res. 2004;78(5):723-731.
40. Lee H, Kim YO, Kim H, et al. Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J. 2003;17(13):1943-1944.
41. Jung KK, Lee HS, Cho JY, et al. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci. 2006;79(21):2022-2031.
42. Nam KN, Son MS, Park JH, et al. Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications. Neuropharmacology. 2008;55(5): 819-825.
43. Nam KN, Choi YS, Jung HJ, et al. Genipin inhibits the inflammatory response of rat brain microglial cells. Int Immunopharmacol. 2010;10(4):493-499.
44. Lee KH, Yun SJ, Nam KN, et al. Activation of microglial cells by ceruloplasmin. Brain Res. 2007;1171:1-8.
45. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85(3):890-902.
46. Jung JE, Lee J, Ha J, et al. 5-Aminoimidazole-4- carboxamideribonucleoside enhances oxidative stress-induced apoptosis through activation of nuclear factor-kappaB in mouse Neuro 2a neuroblasetoma cells. Neurosci Lett. 2004;354(3):197-200.
47. Kaltschmidt B, Kaltschmidt C, Hofmann TG, et al. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur J Biochem. 2000;267(12): 3828-3835.